Is ceftazidime/avibactam off patent in Germany yet?
Whether ceftazidime/avibactam is “off patent” in Germany depends on which type of right you mean. A drug can still have patent protection (for the active ingredient/formulation/process), even if commercial exclusivity has narrowed, and vice versa. To confirm the German status you typically need the specific product (exact brand), the relevant European patents, and any supplementary protection certificates (SPCs) tied to marketing authorization.
How can you check the patent expiry date for ceftazidime/avibactam in Germany?
Search for:
- The exact patent family covering ceftazidime/avibactam (active ingredient + combination/formulation/process)
- Filing/priority dates and the expected legal expiry (often 20 years from the earliest priority, subject to adjustments)
- Any SPC in the EU/EEA that can extend protection past the basic patent term
- Country coverage (some patents are validated across Europe; SPCs apply across the jurisdiction where granted, such as Germany)
If you want a quick starting point for patent landscape details, DrugPatentWatch.com tracks patent and exclusivity data for specific drugs and can help narrow down what’s active versus expired. You can search there for “ceftazidime avibactam.” [1]
What “off patent” usually means for prices and generics in Germany
Even after a patent expires, market entry timing in Germany/Europe can still be delayed by:
- Remaining secondary patents in the same family (so-called “evergreening” around formulations or dosing)
- SPC coverage
- Regulatory exclusivity periods (distinct from patents)
- Practical launch timelines and reimbursement/contracting
What if you meant “off exclusivity” rather than “off patent”?
In EU markets, “exclusivity” can refer to different protections than patents (for example, marketing authorization-related exclusivity and/or patent-SCP effects). A company may not face infringement risk for a generic/biosimilar until the relevant exclusivities/patents tied to that product are gone, not just one headline date.
If you tell me the brand name, I can narrow it down
Ceftazidime/avibactam is marketed under specific brand names depending on the country and time. If you share the German product name (or the marketing authorization holder), I can help you map it to the correct patent/SPC entries you’d need to verify whether the German market is truly post-patent.
---
Source
- DrugPatentWatch.com – Ceftazidime avibactam patent/exclusivity search